ReviewAntimicrobial agents and chemotherapy2016
Optimizing the Clinical Use of Vancomycin.
Review in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antibiotic-laden bone cement for diabetic foot infected wounds: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Vancomycin Dosing in Children With Overweight or Obesity: A Systematic Review and Meta-analysis.Hospital pediatrics · 2020Pooled it
- Impact of ascorbic acid in reducing the incidence of vancomycin associated nephrotoxicity in critically ill patients: A preliminary randomized controlled trial.F1000Research · 2021Trial
- Impact of surface structuring on antibiotic elution from bone cement in two-stage revision for periprosthetic joint infection.BMC musculoskeletal disorders · 2026Article
- Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border.Antibiotics (Basel, Switzerland) · 2026Review
- Impact of vancomycin administration modality on target attainment in acutely ill children-a propensity score matching analysis.European journal of pediatrics · 2026Article
- Advances in Pediatric Therapeutic Drug Monitoring.Pediatrics · 2026Review
- Linear dose-response relationship between vancomycin trough concentration and acute kidney injury in sepsis: effect modification by hyperlactatemia.Frontiers in pharmacology · 2026Article
- The effect of pulsatile lavage on antibiotic elution from bone cements in two-stage revision for periprosthetic joint infection.Journal of orthopaedic surgery and research · 2025Article
- Impact of Obesity on Serum Concentrations of Vancomycin Administered as Continuous Infusion and on Clinical Outcomes in Critically Ill Patients-A Retrospective Observational Study.Antibiotics (Basel, Switzerland) · 2025Article
- Lytic Transglycosylase Deficiency Increases Susceptibility to β-lactam Antibiotics But Reduces Susceptibility to Vancomycin in Escherichia coli.Microbiology and immunology · 2025Article
- Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients.Antimicrobial agents and chemotherapy · 2025Article
- A Successful Experience of Individualized Vancomycin Dosing in Critically Ill Patients by Using a Loading Dose and Maintenance Dose.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Safe and effective use of vancomycin.Australian prescriber · 2025Review
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis.Frontiers in pharmacology · 2025Article
- A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions.Therapeutics and clinical risk management · 2025Review
- Association between vancomycin therapeutic drug monitoring and improved clinical outcomes in critically ill patients receiving renal replacement therapy: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Pharmacokinetic variability of vancomycin in patients undergoing hematopoietic stem cell transplantation: a retrospective cohort study in Peru.Therapeutic advances in drug safety · 2025Article
- Machine learning approach for personalized vancomycin steady-state trough concentration prediction: a superior approach over Bayesian population pharmacokinetic model.Frontiers in pharmacology · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing number of infections produced by beta-lactam-resistant Gram-positive bacteria and the morbidity secondary to these infections make it necessary to optimize the use of vancomycin. In 2009, the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists published specific guidelines about vancomycin dosage and monitoring. However, these guidelines have not been updated in the past 6 years. This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomycin dosing in special situations (obese people, burn patients, renal replacement therapy, among others). Vancomycin efficacy is linked to a correct dosage which should aim to reach an area under the curve (AUC)/MIC ratio of ≥400; serum trough levels of 15 to 20 mg/liter are considered a surrogate marker of an AUC/MIC ratio of ≥400 for a MIC of ≤1 mg/liter. For Staphylococcus aureus strains presenting with a MIC >1 mg/liter, an alternative agent should be considered. Vancomycin doses must be adjusted according to body weight and the plasma trough levels of the drug. Nephrotoxicity has been associated with target vancomycin trough levels above 15 mg/liter. Continuous infusion is an option, especially for patients at high risk of renal impairment or unstable vancomycin clearance. In such cases, vancomycin plasma steady-state level and creatinine monitoring are strongly indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.